Verrica Pharmaceuticals Holds Annual Stockholders Meeting

Verrica Pharmaceuticals ( (VRCA) ) has provided an announcement.

On June 5, 2025, Verrica Pharmaceuticals held its annual stockholders meeting where four proposals were considered. All three director nominees were elected, executive compensation was approved, KPMG LLP’s appointment as the accounting firm was ratified, and a potential reverse stock split was authorized, reflecting strong shareholder support for the company’s strategic decisions.

The most recent analyst rating on (VRCA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.

Spark’s Take on VRCA Stock

According to Spark, TipRanks’ AI Analyst, VRCA is a Neutral.

Verrica Pharmaceuticals faces serious financial challenges, including declining revenues and negative equity, which heavily weigh down the stock score. Despite these issues, positive developments in sales growth and clinical progress partially offset the financial concerns. Technical indicators show some short-term positive momentum, although longer-term trends remain bearish. The earnings call provided a balanced view of both progress and ongoing challenges.

To see Spark’s full report on VRCA stock, click here.

More about Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc. operates within the pharmaceutical industry, focusing on developing and commercializing dermatological treatments. The company aims to address unmet needs in skin diseases, leveraging innovative therapeutic solutions.

Average Trading Volume: 388,274

Technical Sentiment Signal: Sell

Current Market Cap: $49.12M

See more data about VRCA stock on TipRanks’ Stock Analysis page.